Taken together, our findings demonstrate for the first time that NK1R is a potential synthetic lethal partner of CaMKII to eradicate GSCs, and therefore, they suggest a new combination therapy targeting CaMKIIγ and NK1R for GBM treatment. This evidence concerns the gene TACR1 and glioblastoma.